Study wrapper · #981
Exogenous Kisspeptin-10 inhibits ovarian cancer progression through targeting the SP1-hTERT-ZEB1 regulatory axis.
Shah H, Thomas A, Pandya P Cytotechnology. 2026.
DOI: 10.1007/s10616-026-01005-8PubMed: 42292313
Editor's note
This in vitro study applies exogenous kisspeptin-10 to ovarian cancer cell lines and reports anti-metastatic signaling effects. It is cell-culture only, so it is an early mechanistic observation rather than evidence in animals or humans. A genuine kisspeptin-as-agent study but at the weakest tier of evidence.
Plain-language abstract
In cultured ovarian cancer cells, exogenous kisspeptin-10 reduced proliferation, migration, and invasion by acting on the SP1-hTERT-ZEB1 pathway. Effects were seen only in cell lines.
Related coverage
Supported
Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche.
Clinica chimica acta; international journal of clinical chemistryn=——2027
Weak / none
The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54.
Molecular and cellular endocrinologyn=——2026
Mixed
Kisspeptin System: A Modulator of Neuroinflammation and Behaviour in Temporal Lobe Epileptic Rats.
Molecular neurobiologyn=——2026